Ad-hoc | 24 August 2012 14:48
WILEX AG / Key word(s): Capital Increase
24.08.2012 14:48
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)
- Not for distribution, publication or transmission
in the USA, Canada, Japan and Australia -
WILEX AG successfully completes combined capital increase of cash and
contribution in kind totalling EUR 23.9 million
Munich, Germany, 24 August 2012. The Executive Management Board of WILEX AG
(ISIN DE0006614720/WL6/FSE) today resolved with the approval of the
Supervisory Board to set the final number of shares from the combined
capital increase (against cash or contributions in kind) at 6,460,544 new
no par value bearer shares. The subscription and/or purchase price was EUR
3.70 per share.
As contribution in kind, the company's shareholder dievini Hopp BioTech
holding GmbH & Co. KG, Walldorf, Germany, (dievini) converted its existing
loan granted to WILEX AG (plus interest) amounting to approximately EUR
7.77 million to 2,100,337 new shares (32.5% of the total volume of the
capital increase) by exercising subscription rights. As planned, this will
repay the loan from dievini and significantly reduce WILEX AG's financial
liabilities without adversely affecting cash reserves.
The cash rights issue involved existing shareholders exercising the
remaining subscription rights and using the oversubscription option to
acquire 1,682,910 new shares (26.1%). All oversubscription orders were
fulfilled. In addition, 2,677,297 new shares (41.4%) were subscribed in
private placements after the subscription period. The shareholders dievini
and affiliated companies along with UCB Pharma S.A. participated in the
cash capital increase as announced. Overall, 95.5% of the maximum possible
volume was utilised.
Landesbank Baden-Württemberg, Stuttgart, (LBBW) was the sole lead manager
and bookrunner of the transaction.
The total number of WILEX shares issued (share capital) will increase to
31,275,507 shares following the entry of the capital measure in the
Commercial Register, scheduled for 27 August 2012. The new shares are
expected to be admitted to trading on 28 August 2012. It is anticipated
that the subscribed and allotted shares will be delivered on 28 August
2012, but no earlier than their admission to the Regulated Market (Prime
Standard).
WILEX AG will receive gross proceeds of around EUR 16.1 million from the
cash portion of the transaction, which the company will use to finance
ongoing and planned clinical studies as well as future growth. Overall, the
capital measure will improve the Company's equity base by EUR 23.9 million.
+++ End of Ad hoc release +++
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company has a broad portfolio of diagnostic and
therapeutic products for the specific detection and targeted treatment of
various types of cancer. WILEX's therapeutic product candidates are based
on antibodies (RENCAREX(R) in Phase III) and small molecules (MESUPRON(R)
in Phase II, WX-554 in Phase Ib/II and WX-037 in preclinical development).
In the field of diagnostics, REDECTANE(R) is an antibody-based, imaging in
vivo diagnostic agent that is currently in a Phase III programme. WILEX's
US subsidiary WILEX Inc. in Cambridge, MA, markets a portfolio of research
use only tests and in vitro diagnostic agents under the brand Oncogene
Science, which are used as companion diagnostics for clinical trials and
therapy monitoring. The subsidiary Heidelberg Pharma GmbH offers an
attractive and highly promising antibody drug conjugate technology platform
and preclinical contract research services. The business model of WILEX
comprises research, technology, product development and commercialisation.
WILEX's customers and partners include leading international pharmaceutical
companies.
Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6
This ad hoc announcement contains forward-looking statements, which express
the current beliefs and expectations of the management of WILEX AG,
including statements about the Company's future cash position. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to place
undue reliance on the forward-looking statements contained in this ad hoc
announcement. Forward-looking statements speak only as of the date on which
they are made and WILEX undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
This ad hoc announcement is not for distribution, directly or indirectly,
in or into the United States (including its territories and possessions,
any State of the United States and the District of Columbia). These
materials do not constitute or form a part of any offer or solicitation to
purchase or subscribe for securities in the United States of America. The
shares in WILEX AG (the 'Shares') mentioned herein may not be offered or
sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the
'Securities Act').
The Shares have not been, and will not be, registered under the Securities
Act and will not be offered or sold in the United States, except on the
basis of applicable exemptions from registration. There will be no public
offering of securities in the United States or elsewhere.
Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Email: investors@wilex.com
This communication contains certain forward-looking statements, relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by
general discussion of strategy, plans or intentions of the Company. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments. Given these uncertainties, prospective investors
and partners are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update any such
forward-looking statements to reflect future events or developments.
24.08.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------